Urine cytology, tumour markers and bladder cancer

British Journal of Urology

Volumn 82, Issue 5, 1998, Pages 647-654

  Halachmi, S ^a   Linn, J F ^b   Amiel, G E ^a   Moskovitz, B ^a   Nativ, U ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Bladder cancer; Cancer markers; Growth factors; Urinary cytology

Indexed keywords

BLOOD GROUP ANTIGEN; CADHERIN; EPITHELIAL MEMBRANE ANTIGEN; FIBRINOGEN DEGRADATION PRODUCT; GROWTH FACTOR; INTEGRIN; TELOMERASE; TISSUE POLYPEPTIDE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN; TUMOR MARKER;

BLADDER CANCER; CANCER CELL; CANCER INVASION; CELL NUCLEUS MATRIX; HEMATURIA; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; SUPERFICIAL CANCER; TUMOR RECURRENCE; URINALYSIS; URINE CYTOLOGY;

ANTIGENS, NEOPLASM; BLOOD GROUP ANTIGENS; CARCINOMA, TRANSITIONAL CELL; FEMALE; GROWTH SUBSTANCES; HUMANS; MALE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE;

EID: 0031794319     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00821.x     Document Type: Review

References (54)

1. Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettline C, Menck HR. The national cancer data report on bladder carcinoma. Cancer 1996; 77: 1505-13
2. Jezernik K. Medalia 0, Aronson M. A comparative study of the desquamation of urothelial cells during gestation and in adults mice following moderate stress or endotoxin treatment. Cell Biol Int 1995; 19: 887-93
3. Alroy J, Pauli BU, Weinstein RS. Correlation between numbers of desmosomes and the aggressiveness of transitional cell carcinoma in human urinary bladder. Cancer 1981; 47: 104-12
4. Pauli BU, Weinstein RS, Alroy J, Arai M. Ultrastructure of cell junctions in FANFT-induced urothelial tumors in urinary bladder of Fischer rats. Lab Invest 1977; 37: 609-21
5. Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol 1985; 29: 810-6
6. Koss LG. Diagnostic Cytology of the Urinary Tract. Philadelphia: JB Lippincott, 1995
7. Rosenthal DL. Urologie cytology. In Astarita RW, ed. Practical Cytopathology. New York: Churchill Livingstone. 1990: 303-36
8. Wiener HG, Vooijs GP, van't Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 1993; 371: 163-9
9. Orihula 0, Srinivas V, Herr H, Melamed M, Whitmore JW. The practical use of tumor marker determination in bladder washing specimens. Cancer 1987; 60: 1009-16
10. Srinivas V, Khan A, Hoisington S, Varma A, Gonder M. Relationship of blood groups and bladder. J Urol 1986: 135: 50-60
11. Konety R, Getzenberg R, Bahnson R. Diagnostic and prognostic markers in bladder cancer. Contemp Urol 1996; July: 15-35
12. Sheinfeld J. Reuter V, Melamed M et al. Enhanced bladder cancer detection with Lewis X antigen as a marker of neoplastic transformation. J Urol 1990: 141: 285-8
13. Cordon-Cardo C. Reuter V. Lloyd K, Sheinfeld ], Old L. Melamed M. Blood group related antigens in human urothelium: enhanced expression of precursor Lex and Ley determinants in urothelial carcinoma. Cancer Res 1988; 48: 4113-20
14. Pode D, Golijanin A. Sherman Y. Lebensart P. Shapiro A. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998; 159: 389-93
15. Golijanin A. Sherman A, Shapiro A. Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 1995; 46: 173-7
16. Barton H. Lieberl M. Sakakibra N, Wedemeyer G, Stein J, Washington R. Evaluation of new bladder tumor marker. Urol Clin North Am 1991: 18: 509-13
17. Sanchez-Fernandez de Sevilla M. Morell Q, Perez-Bacete M. Fenollosa-Entrena B. Llombart-Bosch A. Behavior of epithelial differentiation antigens (Carcinoembryonic antigen, epithelial membrane antigen, keratin and cytokeratin) in transitional cell carcinoma of the bladder. Urol Int 1992: 48: 14-9
18. Huland H. Arndt R. Huland E. Loening T, Steffens M. Monoclonal antibody 486p 3/12: a valuable bladder carcinoma marker for immunocytology. J Urol 1987; 137: 654-9
19. Huland E. Huland H, Scneider A. Quantitative immunocytology in the management of patients with superficial bladder carcinoma. Marker to identify patients who do not require prophylaxis. J Urol 1990: 144: 637-40
20. Huland E, Huland H, Meier T et al. Comparison of 15 monoclonal antibodies against tumor associated antigens of transitional cell carcinoma of the human bladder. J Urol 1991: 146: 1631-6
21. Cordon-Cardo C, Wartinger D. Melamed M, Fair WR. Fradet Y. Immunophatology analysis of human urinary bladder cancer. Am JPathol 1992; 140: 375-85
22. Van Popel H. Billen J, Goethuys H et al. Serum tissue polypeptide antigen (TPA) as a tumor marker for bladder cancer. Anticancer Res 1996: 16: 2205-8
23. Filella X. Mendez V, Molina R. Alcover J, Carretero P. Ballesta A. TPA prognostic value in superficial bladder cancer. Anticancer Res 1996: 16: 2173-6
24. Vleminckx K. Vakaet L Jr. Marcel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-19
25. Bringuier PP. Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993; 53: 3241-5
26. Shimazui T, Schalken JA. Giroldi LA et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and pl20cas) in bladder tumors. Cancer Res 1996: 56: 4154-8
27. Cells J. Rasmussen H. Vorum H et al Bladder squamous cell carcinoma express psoriasin and externalize it to the urine. J Urol 1996: 155: 2105-12
28. Liebert M, Washington R, Stein J, Wedemeyer G, Grossman H. Expression of the VLAbl integrin family in bladder cancer. Am JPathol 1994: 144: 1016-22
29. Chopin D. Caruelle J. Colombel M et al. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 1993; 150: 1126-30
30. Ravery V, Jouanneau ], Gil Diez S et al. Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol Res 1992: 20: 211-4
31. Sporn M. Roberts A. Transforming growth factor β: multiple actions and potential clinical applications. JAMA 1989: 262: 938-41
32. Wilding G, Knabbe C, Zugmaier G, Flanders K. Differential effect of TGF on human prostate cancer cells in vitro. Moke Cell Endocrinol 1989: 62: 79-87
33. Miyamoto H, Kubota Y, Shuin T. Torigoe S, Dobashi Y. Hosaka M. Expression of transforming growth factor beta 1 in human bladder cancer. Cancer 1995: 75: 2565-70
34. Sarosdy M. deVere White R. Soloway M et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995; 154: 379-84
35. D'Hallewin M. Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 1996; 155:475-6
36. Halachmi S, Enger S, Rosenthal D, Sidransky D, Schoenberg M. Molecular diagnosis and staging of bladder cancer. J Mol Urol 1997; 1: 309-13
37. Ishak L. Entield D. Detection of recurrent bladder cancer: a new quantitative assay for bladder tumor antigen. J Urol Suppl 1997; 157: 337
38. Soloway MS. Briggman J. Carpinito A. Chodak G. Church P, Lamm D et al. Use of a new tumor marker, urinary NMP22 in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996: 156: 365-7
39. Carpinito A. Stadler W. Briggman J et al. Urinary nuclear matrix protein (NMP22) as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996: 156: 1280-5
40. McCabe R. Lamm D. Haspel M et al. A diagnostic-prognostic test for bladder cancer using a monoclonal antibody based enzyme linked immunoassay for detection of urinary fibrin(ogen) degradation products. Cancer Res 1984; 44: 5886-93
41. Johnston B. Morales A. Emerson L. Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997; 158: 2098-101
42. Mao L. Schoenberg MP. Scicchitano M et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271: 659-62
43. Steiner G. Schoenberg MP. Linn JF, Mao L. Sidransky D. Detection of bladder cancr recurrence by microsatellite analysis of urine. Nature Med 1997; 3: 621-4
44. Blackburn EH. Structure and function of telomeres. Nature 1991: 350: 569-73
45. Califano J, Ahrendt SA, Meininger G, Westra WH, Koch WM, Sidransky D. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res 1996; 56: 5720-2
46. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995; 55: 2533-6
47. Counter CM. Hirte HW. Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sei VSA 1994; 91: 2900-4
48. Yoshida K. Sugino K, Tahara H et al. Telomerase activity in bladder carcinoma and its implication for non invasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997: 79: 362-9
49. Muller M. Heine B. Heicappell R et al. Telomerase activity in bladder cancer, bladder washings and in urine. Int JOncol 1996; 9: 1169-73
50. Kyo S, Kunimi K, Uchibayashi T, Nakimi M, Inoue M. Telomerase activity in human urothelial tumors. Am JClin Pathol 1997; 107: 555-60
51. Linn JF. Lango MN. Halachmi S, Schoenberg MP, Sidransky D. Microsatellite analysis and telomerase activity in archive tissue and urine samples of bladder cancer patients. Int JCancer 1998; 74: 625-9
52. Fodor SPA, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D. Light directed, spatially addressable parallel chemical synthesis. Science 1993; 251: 767-73
53. Editorial. To affinity and beyond. Nature Genet 1996; 14: 367-70
54. Sarosdy M. Data interpretation and integration of new tests into clinical practice. J Urol 1997; 158: 2107-8